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Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease (ILD) 
classified under idiopathic fibrotic disorders of the lung. It is the most common 
type of ILD presenting clinically in the seventh decade of life, almost always at 
the later stage of illness, attributed to its earlier nonspecific presentation. The 
term IPF is used when no specific cause for pulmonary fibrosis is identified. 
Initially described in 1944, recent advances in lung biopsy and pathology have 
described the disease in detail. This led to further classification of ILD. Also, there 
have been multiple recent studies indicative of an increased incidence. However, 
accurate epidemiological data for IPF is minimal, with some being contradictory. 
Inconsistency in the case definition criteria and methodology has resulted in 
epidemiological inaccuracy when used to detect patients in the study population. 
To avoid inaccuracy American Thoracic Society collaborated with the European, 
Japanese, and Latin American Thoracic Society to arrive at a consensus resulting 
in 2010 IPF evidence-based guidelines. Notable epidemiological differences are 
observed in the European, American, and Asian countries. Some countries have 
set up national registries to collect essential patient data for future studies and 
comparison with other countries. In this topic, we try to glean over the epidemiol-
ogy of IPF.
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1. Introduction
IPF is a rare pulmonary disease affecting patients often in their sixth or the 
seventh decade of life. The disease course is progressive, causing permanent 
damage to the pulmonary tissue resulting in restrictive lung disease and hypoxia. 
Pharmacological therapeutic options are sparse and limited to new medications 
such as nintedanib and pirfenidone [1]. Without lung transplantation, IPF is lethal, 
and the patient dies from acute pulmonary failure in two to four years on average 
[1]. Lung transplantation has altered the disease course and improved longevity. 
As it is a rare disease, an accurate, consistent epidemiological methodology needs 
to be followed for data collection to measure the incidence and prevalence of 
IPF [1]. The consensus evidence-based guidelines in 2011 guide how to arrive at 




2. Predisposing risk factors
2.1 Age and gender
As the patient’s age increases, the IPF incidence increases with a more significant 
occurrence in men than women as per epidemiological studies [2]. The mean age at 
which diagnosis was established was 66 years. On average, most patients diagnosed 
with IPF lie between the age of 40 to 70 years [3]. Occurrence in younger patients 
(< 40 years) is rare. In most studies, men accounted for most cases except for a 
Norwegian study which disclosed a higher prevalence in females [4]. A recent 
study with an IPF score algorithm was generated using logistic regression to mea-
sure the exact incidence and prevalence values of 14.6/100,000 person-years and 
58.7/100,000 person-years. The IPF score algorithm had a positive predictive value 
(PPV) of 83.3% [1].
The Gender-Age-Physiology (GAP) index calculated to predict IPF mortality 
by dividing the IPF into three stages GAP one, two, and three did not anticipate 
a decline in pulmonary function based on the severity of the GAP index [5]. IPF 
disproportionately affecting 71% of males was observed in a recent retrospective 
cohort study [6]. Age-adjusted males were strongly linked to an increased risk 
(40%) for lung transplantation or death [6]. In males, the cough was associated 
with dyspnea due to smoking-related airway disease, whereas in females, it was due 
to acid reflux disease. A lower diffusion capacity than predicted for age, senility, dry 
or productive cough with phlegm correlated with a decreased survival in males free 
of transplant compared to females. This may be due to excessive male exposure to 
risk factors in the environment, such as cigarette or occupational smoke particulate 
material and sex hormones [6]. Sex hormones modulate the immune system with a 
humoral immune response augmentation by estrogen and androgens, suppressing 
the cell-mediated and humoral immune response [7].
Age is a substantial independent predictor of IPF [8]. Aging lung undergoes 
anatomical and physiological changes predisposing it to IPF. The elderly may have 
abnormal recruitment of protective mesenchymal cells and fibrocytes in response 
to acute lung injury [9]. Increased endoplasmic reticulum oxidative stress, unfolded 
protein response lead to apoptosis of type 2 alveolar epithelial cells increasing suscep-
tibility to IPF in the elderly [10]. Immune changes are seen in adaptive than in innate 
immunity. Adaptive immunity changes affect the T lymphocytes more than the B 
lymphocytes. There is a decrease in differentiation, antibody affinity, and interac-
tion with T cells & B cells. There is a decline in naïve T cells (with short telomere and 
restricted repertoire), transition to Th2 response phenotype, an abnormal increase in 
memory, and effector cells with large CD28 deficient CD8 endstage clonal population 
[11, 12]. The T cell response leads to an inadequate vaccination and abnormal viral 
response [13, 14]. Many IPF patients have a shorter telomere with no detectable muta-
tion in telomerase [15]. The elderly with a short telomere on exposure to susceptible 
environmental exposure may trigger apoptosis resulting in fibrosis. Old lungs may 
provide the appropriate local milieu for gammaherpesvirus or any other virus to cause 
fibrosis [9]. Smoking promotes epigenetic changes in deoxyribonucleic acid methyla-
tion, histone modifications, and microribonucleic acid [16].
Increased mortality in IPF is associated with a consecutive increase in oxygen 
desaturation episodes during a six-minute walk test. Males during their disease course 
experienced frequent faster desaturation events than females. In contrast to males, 
the disease progression rate is slower, in females contributing to survival differences. 
This may contribute to but does not entirely inform more remarkable female survival 
in IPF. Even in fibrotic diseases, females have lesser fibrosis than males, possibly 
due to sex hormone exposure [17]. Most females at their diagnosis of IPF are in a 
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postmenopausal state with diminished estrogen levels. The precise role of hormonal 
imbalance on the fibrotic process needs clarification with further studies.
2.2 Smoking
Smoking is a practice of burning raw or refined tobacco plant leaves and breath-
ing in the resulting smoke for taste. Smoking is an ancient frequent recreational 
drug use still in practice. Tobacco smoke contains multiple active chemicals which 
are either absorbed in the mucosa or delivered to the lungs. Tobacco smoke expo-
sure results in multiple lung diseases such as chronic obstructive pulmonary disease 
(COPD) and lung cancer. Tobacco smoke contains numerous chemicals exerting 
various delirious cellular effects on multiple organs affecting their metabolic 
function. As a primary intermediary, the lung faces the brunt of tobacco smoke 
exposure in active and passive smokers. Tobacco smoke exposure contains acrolein, 
benzene, benzopyrene, acetaldehyde, formaldehyde, carbon monoxide, 1,3-butadi-
ene, and tobacco-specific nitrosamines with human toxicity potential. Additionally, 
the long-term effects of flavors and additives used in cigarettes on tobacco smoke 
and lung are unknown. Another issue is the lack of regulation regarding perfor-
mance standards for ingredients used in making cigarettes [18].
Smoking has been included as a potential etiologic agent recently over the last 
few decades due to its significant prevalence among the IPF patient population 
[19]. However, the association was proposed as early as 1969, which independently 
increases the significant risk of IPF disease [20]. Another disease that shares the 
pathological features of COPD and IPF, known as combined pulmonary fibrosis 
and emphysema (CPFE), is seen predominantly in male smokers. Smoking may 
also enhance the systemic immune response to numerous environmental etiologi-
cal agents, increasing the IPF risk by 60% in smokers [21]. The cytological effect 
of smoking in IPF can be direct or indirect, impacting the clinical course and 
survival. The evidence for a direct effect of smoking causing pulmonary fibrosis 
is minimal [22]. Tobacco use prevalence in IPF patients ranges from 41–83%, the 
range attributed to the definition criteria used in various studies [3, 23]. Alveoli is 
the main target of the IPF, resulting in diminished diffusion capacity for carbon 
monoxide. Alveolar wall fibrosis seen in smokers is due to cigarette smoke exposure, 
and there is an increase in fibrosis based on the duration and intensity of exposure 
[24]. Increased oxidative stress in current and ex-smokers may promote IPF disease 
progression [25]. IPF is also known as senescence disease due to its occurrence in 
tobacco smoke exposure patients’ in an age-dependent style [26].
Smoking results in a small airway inflammatory cell recruitment compris-
ing neutrophils, macrophages, and langerhans cells, resulting in severe immune 
and other lung cell defects. However, only a few patients end up having clinically 
significant diffuse lung disease. Probably only a minority of patients progress into a 
vicious inflammation cycle resulting in IPF due to constant environmental stimuli 
and lapse of anti-inflammatory mechanisms [23]. A brief outline of the IPF patho-
genesis is explained in Figure 1 [19]. Persistent cigarette smoke exposure (CSE) 
leads to a predominant M2 macrophage activation in the lung. In contrast to the M1 
Phenotype, the M2 macrophages are ineffective in host defense, inadequately clear 
noxious agents, and increase fibrotic mediators synthesis.
This results in a vicious, inflammatory cascade causing an increased expression 
of transforming growth factor α 1 (TGF α 1), epidermal growth factor (EGF), and 
mixed metalloproteinase (MMP) expression on epithelial cells leading to an epithe-
lial to mesenchymal transition of the epithelial cells. This increases the pulmonary 
myofibroblasts, which are relatively resistant to apoptosis, have a lower activation 
threshold, augmented profibrotic response, and are activated by apoptosis debris. 
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This leads to an abnormal increase in lung parenchyma myofibroblasts, profibrotic 
mediators, profibrotic receptor expression, and epithelial cell apoptosis. Finally, 
the lung parenchyma changes kick in with increased extracellular matrix (ECM) 
deposition making it difficult for gas exchange. The thick ECM increases lung 
contractility and decreases lung compliance.
Telomere dysfunction noted in the epithelial precursor cells simulating senes-
cence can be seen sporadically and in patients with genetic abnormalities [27]. In 
IPF, the primary cell type affected is the alveolar epithelial precursor cell. The Wnt 
and the Notch signal pathways are essential in sustaining and separating the precur-
sor cells (epithelial and mesenchymal). Defective functioning of these pathways 
results in pneumocyte loss followed by significant inflammation during defective 
attempts at repair due to molecular signals’ release [27]. Smoking causes a decrease 
in histone acetylation and methylation, resulting in the antifibrotic cyclooxygen-
ase-2 gene and interferon-gamma inducible protein suppression [19].
In an earlier study comparing survival disparities and smoking status in IPF 
patients, smokers had lower survival than nonsmokers [27]. Lifetime nonsmokers 
Figure 1. 
Pathogenesis of idiopathic pulmonary fibrosis. RONS, reactive oxygen and nitrogen species; TGF, transforming 
growth factor; EGF, epidermal growth factor; MMP, matrix metalloproteinase; IL, interleukin.
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had a better outcome than prior smokers and the combination of all smokers, 
including active and ex-smokers. This survival disparity suggests that smoking 
results in a decrement of IPF patient’s survival. Current smokers had better survival 
than former smokers due to a healthy smoker effect [27]. The reasoning for this 
effect is that a smoker with the advanced symptomatic disease will quit smoking for 
health benefits. In a recent study analyzing differences in severity adjusted survival 
among active and prior smokers, active smokers’ minimal survival benefit dimin-
ished on adding age to the model [28]. The healthy smoker effect was absent in 
this study. The earlier study’s survival disparity was not apparent after a composite 
physiologic index (calculated from the pulmonary function tests) was added to the 
severity adjustment [27].
Current smokers are younger than ex-smokers and nonsmokers, explaining the 
more prolonged survival seen in these patients [28]. Smoking-associated comor-
bidities were frequent in current smokers with more pack-years of smoking than 
ex-smokers [28]. The frequent comorbidities associated with smoking include 
cardiovascular disease (CVD), coronary artery disease, hypertension, cerebrovas-
cular disease, diabetes, and heart failure may affect IPF mortality. Females had a 
higher incidence of asthma and diabetes than males, while active smokers had a 
higher incidence of COPD and lung cancer than nonsmokers. In the recent study, 
only a diagnosis of CVD, COPD at any time, and insulin use at the time of diagnosis 
resulted in a poor survival on severity adjustment analysis [28]. Smoking preven-
tion is an important cause to decrease mortality and morbidity in the western and 
third world.
2.3 Environmental factors
Occupational disclosure to surrounding elements contributes around 26% 
population attributable fraction (PAF) of total cases of IPF [29]. This suggests that 
IPF is a heterogeneous disease. Exposure to environmental agents occurs during 
the occupation, residence in a specific area, and recreational activities. The expo-
sure may be due to a single agent or multiple agents, which is difficult to quantify. 
Recently air pollution has been recognized as a critical etiology and an exacerbating 
factor for IPF [30]. In comparison to the population size exposed to these agents, 
only a few develop IPF. IPF occurs more so in individuals with genetic susceptibili-
ties exposed to these environmental agents. There are three factors essential in the 
pathogenesis of IPF; one is the environmental agent exposure, the second is the 
duration of exposure, while the third is the host response to the persistent exposure 
controlled by genetic susceptibility. Persistent environmental agent exposure results 
in a biochemical reaction (in most cases oxidative stress) followed by an insistent 
immune response to the agent, causing lung fibrosis [31]. As IPF is a rare disease, 
case–control studies are best suited for it. They come with many challenges regard-
ing data collection as they are subjected to multiple factors that dilute the study’s 
purpose. These factors include disease misclassification (pneumoconiosis classi-
fied as IPF), exposure misclassification (recall bias), and variable susceptibility to 
fibrogenic agents(dose and duration of exposure along with genetic susceptibilities) 
[31]. Adequate clinical significance is denied to occupational and environmental 
history when clinical information is obtained from the patients. Pulmonary tissue 
biopsy analysis in IPF patients with Particle induced X-ray emission revealed a high 
content of silicon, magnesium, titanium, and high surface silicon to a sulfur ratio 
[32, 33]. Elementary analysis of hilar and mediastinal lymph nodes using fluores-
cent x-ray analysis disclosed high nickel content and a minimum silicon elevation 
[34]. Over the last two to three decades, multiple case–control investigations have 
identified various environmental agents suspected to be a causative factor for 
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IPF [35]. These include metal dust (brass, aluminum, arsenic, cadmium, copper, 
molybdenum, tungsten, cobalt, uranium, vanadium, lead, and steel), raising birds, 
farming, wood dust, hairdressing, stone cutting/polishing, and organic dust from 
livestock & vegetation.
A southern European case–control study found two occupations with an 
increased prospect of having IPF, which increased with the exposure duration. One 
group included the farmers, veterinarians, gardeners, and the other group included 
metallurgical and steel industry workers [36]. A self-reported exposure history 
correlated with the increased risk, and the authors evaluated the history with a 
job-exposure matrix (JEM). Although an American multicenter study identified 
multiple jobs related to an increased risk of IPF, the multivariate regression model 
revealed the strongest link between raising birds and exposure to vegetable or 
animal dust [37]. Three occupations in the United States of America (USA), namely 
metal mining, wood building (mobile homes), and structured metal fabricated 
products, had an increased IPF mortality risk based on the mortality data [38]. 
A Korean study on dust exposure divulged its impact on IPF patient’s prognosis. 
Patients with exposure had an earlier IPF diagnosis, prolonged symptom duration 
at diagnosis, and increased mortality than those with no exposure [39].
Organic dust involves farming, gardening, animal husbandry, poultry farming, 
carpentry, and pesticides. Animal husbandry is an agriculture branch related to ani-
mal rearing for food and other products with significant exposure to animal feeds, 
products, and waste. A multicenter case–control study done in Egypt was the first 
to reveal an increased IPF risk in females than males [40]. Females were at a higher 
risk while working in poultry farming, farming with organic dust, and occupational 
pesticide exposure. Males carried an increased risk in carpentry, chemical, and 
petrochemical industries occupations. Both sexes had an increased risk with cat or 
bird exposure. IPF risk was minimal in sales and clerical jobs [40]. A Belgian mul-
tidisciplinary team studied 244 IPF patients, divided them based on prior exposure 
to molds or birds, and simultaneously compared them to chronic hypersensitivity 
pneumonitis patients. Patients exposed to birds or molds were associated with a 
decreased fatality than unexposed patients [41].
Mineral and metal dust exposure are well known to increase the IPF risk. A 
British study done in a major engineering company evaluated IPF mortality in 
employees exposed to occupational metal exposure. It revealed a strong association 
between IPF fatality and metal exposure strength and duration [42]. A multicenter 
Japanese study disclosed that patients with clerical occupations had a lower risk of 
IPF than patients with prior metal exposure [43]. Hilar lymph nodes histopatho-
logical analysis in IPF patients compared to controls revealed excess aluminum 
and silicon related to an increased risk of IPF [44]. Two smaller South Korean 
case–control studies revealed an increased IPF risk with exposure to stone, sand, 
silica, and metal dust [45, 46]. Asbestos occupational exposure results in asbestosis 
are well established; however, the effects of mild to moderate exposure on IPF are 
unclear. A study comparing United Kingdom (UK) asbestos imports per year to IPF 
mortality for any relationship was done. The overall asbestos exposure outcome was 
not addressed in this study. Linear regression models revealed a significant positive 
linear association between imports and IPF mortality, suggesting an association 
between IPF mortality and asbestos exposure [47]. UK is undergoing a national 
study by the name IPF Job Exposure study (IPF-JES) to evaluate the IPF risk associ-
ated with occupational asbestos exposure.
Wood dust exposure during carpentry and woodworks is related to a higher IPF 
risk and follows a dose–response association in UK based case–control study [48]. A 
Swedish multicenter case–control study on occupational exposure revealed a higher 
IPF risk in males with birch dust and hardwood dust exposure and no increased risk 
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with metal exposure [49]. A similar increased association was observed in an Italian 
case series and an Egyptian multicenter case–control study [40, 50]. Air pollut-
ants present in the environment may have an important role apart from smoking 
in IPF incidence. An Italian study evaluated the relationship between IPF occur-
rence in patients persistently exposed to ambient air pollutants (nitrogen dioxide, 
particulate matter [aerodynamic diameter less than 10 μm], and ozone) [30]. Final 
results were not adjusted for smoking which was a limitation of this study. An 
increment in nitrogen dioxide concentration resulted in a significant IPF incidence 
rate increase with no association observed with ozone and particulate matter. IPF 
acute exacerbation risk is higher in patients exposed to nitrogen dioxide and ozone 
in the prior six weeks [51]. Conflicting results of studies on lung function decline 
on ambient particulate matter (APM) exposure have been observed. One study 
revealed an accelerated lung function decrement in patients exposed to APM with 
an aerodynamic diameter of less than 10 μm, and no relationship was noted with 
APM with an aerodynamic diameter of less than 2.5 μm [52]. No association with a 
lung function decrease rate and ambient air pollutant exposure was identified in a 
25 patient prospective group study [53]. A large French cohort study evaluated the 
effect of air pollutants on IPF disease outcomes [54]. Patients exposed to ozone had 
a higher risk of IPF acute exacerbations, whereas those exposed to APM with an 
aerodynamic diameter of less than 10 or 2.5 μm had increased mortality. In conclu-
sion, APM exposure regularly can play a role in pathophysiology and may affect IPF 
disease progression.
A 2019 meta-analysis reviewed the literature and case–control studies. The 
following exposures (metal dust, silica, wood dust & vapor, gas, dust, or fumes) 
were significant statistically [29]. The pooled odds ratio for agricultural work was 
elevated with no significance. A recent South Korean meta-analysis revealed a 
statistically significant association with pesticide, metal, and wood dust exposure. 
No significance was observed with stone or sand dust and textile dust exposure. 
Agricultural workers and woodworkers had a significant increase in IPF risk sta-
tistically, whereas no significance was seen in textile workers [55]. In this Japanese 
study, consumption of fish rich in polyunsaturated fatty acids had a significantly 
lower odds ratio with regards to IPF, and it may have a suppressive effect on lung 
fibrosis [56]. A decline in IPF rate is achievable if environmental exposure is 
modified. It is a demanding process to obtain a detailed exposure history as it is 
subject to recall bias, difficulty in quantifying heterogeneous exposure intensity 
and its cumulative variation [57]. Also, it is difficult to identify a specific exposure 
effect when multiple are in play. For obtaining accurate epidemiological data, a 
standard operational definition for occupational and environmental history needs 
to be arrived at based on consensus so that it is easier to compare multiple studies 
(case–control and cohort) precisely to understand the IPF occurrence. If occupa-
tional and environmental exposure results in IPF, implementing measures to alter 
the exposure or improve the occupational environment may decrease IPF risk, and 
prevention may become a public health issue.
2.4 GERD (gastroesophageal reflux disease)
Gastroesophageal disease is a suspected risk factor for IPF development and 
progression currently under intense debate [58, 59]. The prevalence of pulmonary 
fibrosis was statistically significant in veterans with GERD history compared to 
healthy controls [60]. GERD incidence in IPF is higher than the average population 
and ranges from 8–87%. The variation is due to the methods used in diagnosis, 
diagnosis definition used and the types of data collected [61–63]. The greater 
incidence could be due to the common risk factors such as smoking and aging [64]. 
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The gastroesophageal abnormalities seen in IPF patients include transient lower 
esophageal sphincter (LES) relaxations, decreased upper esophageal sphincter tone, 
and significantly greater proximal esophageal acid exposure cumulatively [65]. 
The decreased lung compliance in IPF due to fibrosis creates a negative intrapleural 
pressure which on transmission to the intrathoracic area decreases the LES tone 
resulting in reflux [66]. In animal models, the burden of proof is most substantial 
for GERD associated with IPF [67]. Chronic microaspiration insults may lead to 
pulmonary parenchyma damage attracting persistent inflammation resulting in 
fibrotic remodeling [68, 69]. Tracheal pepsin is a predictable indicator of aspiration 
[70]. The presence of bile salts and pepsin in bronchoalveolar lavage (BAL) sug-
gests both acidic and nonacidic refluxate as risk factors for IPF disease [71]. BAL 
pepsin levels in post-transplant IPF patients were higher than in other chronic lung 
diseases [72].
PPI (Proton pump inhibitors) used in GERD are a reactive oxygen species 
scavenger, stimulate antioxidant production, decrease pro-inflammatory cytokines, 
inhibit profibrotic molecule expression, and decelerate pulmonary epithelial cell 
apoptosis [73]. Multiple studies and metanalysis have reviewed the use of PPI in IPF 
patients for GERD. Initial studies revealed PPI use was associated with fewer acute 
exacerbations, lower hospitalization rates, lesser radiological fibrosis score, stable 
or improved lung function, and more extended transplant-free survival [59, 74–76]. 
GERD symptoms and pathophysiology are well addressed by LARS (Laparoscopic 
antireflux surgery) as it restores the gastroesophageal junction anatomy and con-
trols both acidic and nonacidic reflux [65]. IPF patients post-LARS had a nonsig-
nificant decline in acute exacerbations, hospitalization related to pulmonary issues, 
and death than the nonsurgical group in a small group of 72 patients [77]. A pooled 
analysis on the antacid treatment effect on disease progression in IPF placebo 
patients included in the pirfenidone trials revealed no improved outcomes [78]. 
Instead, advanced IPF patients on antacid therapy had a greater risk of pulmonary 
and nonpulmonary infections. PPI use in IPF patients has given mixed results in 
studies, possibly due to their inability to correct the GERD anatomy. PPI can only 
alter the gastric refluxate’s pH, making it more alkaline with no acidic and nonacidic 
microaspiration prevention [65]. A meta-analysis and systematic review evalu-
ated the efficacy and safety of GERD therapy in IPF [79]. It revealed a significant 
decline in acute exacerbations, mortality related to IPF, and improved transplant-
free survival. GERD pharmacological therapy did not result in all-cause mortality 
reduction. Another meta-analysis via systematic review analyzed the GERD and 
IPF association, and it revealed a possible association confounded by smoking [80].
In a post-hoc data evaluation of the INPULSIS trials, IPF acute exacerbations 
frequently occurred on antacid therapy than those not on it [81]. PPI use results 
in alkaline gastric pH, which loses its bactericidal effect and increases respiratory 
infections on aspiration [69]. The clinical data available does not agree with a GERD 
and IPF relationship [82]. In most patients, refluxes are silent with the absence 
of any symptoms, and the best way to diagnose them is via esophageal MII-pH or 
high-resolution manometry. Alternatively, bronchoscopy with BAL presence of 
pepsin and bile salts can be used in IPF [69]. During meta-analysis, a lack of clarity 
with GERD diagnostic definitions was identified. It was difficult to pinpoint which 
criteria were used to select the patient and how many met them. [78]. The hetero-
geneous methods used have made it difficult to assess the association. Meta-analysis 
always encounters various issues with case–control studies and requires accurate 
interpretation of the association, however small it may be [83]. More extensive 
randomized trials are needed to study the effect of LARS in IPF patients. Future 
prospective studies would be better suited to accurately evaluate the evidence and 
analyze the PPI effect on the IPF clinical course.
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2.5 Viral infections
The role of viral infections in IPF pathogenesis is unclear. It could either be an 
initiator of IPF or could exacerbate a preexisting disease based on the type of viral 
infection. Immunosenescence predisposes old lungs to viral infections due to T cell 
inefficiency. Lack of improved outcomes on the treatment of IPF with immunosup-
pressants indicates the need for an intact immune system to control the disease 
process [84]. IPF therapy with antiviral medications has improved pulmonary 
function [85, 86]. Herpesvirus deoxyribonucleic acid (DNA) was recovered in 97% 
of IPF subjects compared to 36% of controls. This supports the idea of a herpes 
virus causing chronic antigenic stimulation in lung tissue [85]. Multiple animal 
models have supported a virus as an etiology for IPF. Experimental horse infection 
with an equine gammaherpesvirus resulted in pulmonary fibrosis [87]. Murine 
infection with a Murine herpesvirus 68 (MHV 68) two to 10 weeks before introduc-
ing a fibrotic insult accelerated lung fibrosis even in the presence of a weaker insult 
[88]. MHV68 pulmonary installation in an old mouse leads to pulmonary fibrosis 
due to the upregulation of TGF β, which was absent in the younger mice [89]. 
MHV 68 can cause lung fibrosis after a stem cell transplant in animal models [90]. 
MHV 68 infection after a fibrotic lung insult can result in fibrosis [91]. MHV 68 in 
interferon-gamma deficient mice causes pulmonary fibrosis [92].
Serological evidence against herpes virus was detected in IPF patients, including 
Epstein–Barr virus (EBV), Cytomegalovirus (CMV), Herpes simplex virus 1. CMV 
antibodies were present in 80% of patients with IPF compared to 30% of control 
subjects [93]. EBV antibodies were recovered in 60% of IPF patients versus 22% 
and control in another study [94]. EBV DNA presence in the lung relates with 
arterial sclerosis and an increase in pulmonary hypertension suggestive of an 
influence in pulmonary hypertension development [95]. 96% of IPF lungs were 
positive for EBV DNA versus 71% of controls [96]. 9 out of 29 IPF patients had viral 
latent membrane protein in the epithelial cells compared to none in control. 61% 
of IPF patients with a lung biopsy revealed the productive EBV rearrangement of 
DNA [97]. Herpes saimiri DNA was detected in the regenerating epithelium in all 
IPF patient lung biopsy compared to none in control [98]. Herpes saimiri causes 
infection in 7% of humans, and this infection rate is suggestive of it as an etiologi-
cal agent for infrequent sporadic IPF [99]. MHV 68 has high homology to Herpes 
saimiri. In sporadic IPF cases, two or more herpesviruses were detected in the lung 
than a single herpesvirus identified in the familial IPF cases. In the familial IPF 
cases, the virus was either CMV or Human herpesvirus 8 (HHV 8) [85]. At-risk 
family members of IPF patients revealed the presence of epithelial dysfunction and 
fibrotic remodeling. Biopsy specimens revealed herpesvirus antigen elucidation in 
alveolar epithelial cells, and a cell-free BAL sample revealed herpesvirus DNA.
Adenovirus gene product E1A upregulates TGF-beta and stimulates epithelial 
cells to express mesenchymal markers [100]. Administration of adenovirus into 
the airway resulted in an acute inflammatory lung response followed by fibrosis 
in a dose-dependent manner [101]. In IPF patients, serology has not revealed 
significant adenovirus antibodies compared to controls. A Japanese study revealed 
hepatitis C (HCV) antibodies in 28% of IPF patients compared to 3.6% of a 
controlled cohort [102]. IPF incidence in HCV patients was greater at ten years 
and 20 years after the infection [103]. In another study involving 62 IPF patients, 
serology revealed HCV antibodies’ presence in only one patient, indicating no 
increased prevalence [104]. Torque-Teno Virus (TTV) single-stranded DNA virus 
was the most frequent one identified in IPF patients with acute exacerbation 
[105]. Although it was detected in 36.4% of IPF patients, about 50% died in four 
years [106]. TTV DNA titer reflects the host’s immunosuppressive state due to 
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treatment [107]. Experimental Human Boca virus subtype one infection in human 
cell culture lines causes respiratory disease and can persist in the lung causing 
chronic lung disease triggering fibrogenesis [108]. Human Boca virus was isolated 
from BAL in 2 patients in Germany who presented with acute usual interstitial 
pneumonia due to human bocavirus infection [109].
Two studies evaluated the presence of viral infection in acute IPF exacerbation. 
In the first study, most cases of acute exacerbation did not have any viral infec-
tions. Only TTV was identified in a substantially small number of cases [105]. In 
the second study, viruses were detected on the nasopharyngeal swabs in 60% of 
acute IPF exacerbation cases than 43.3% of stable patients. In this study, none of the 
patients were on any corticosteroids or antimicrobials. In acute cases, the inflamma-
tory cytokines were elevated than in stable IPF and controls [110]. A meta-analysis 
of retrospective studies disclosed that chronic infection with CMV, EBV, HHV 7 & 
8 substantially increased the risk of IPF without acute exacerbation of IPF. HHV 6 
was not related to any significant risk of IPF. A nonsignificant greater risk of IPF 
was seen in younger patients with viral infections [111]. Viral infections predispose 
aged lungs to fibrosis, either by reactivating the infection or via latency promot-
ing epithelial to mesenchymal transition. Latent infections alter the local milieu 
by increasing profibrotic mediators but cannot cause fibrosis by themselves and 
need another local lung insult. Latent viral infection is ineffective in causing acute 
exacerbations in animal models. The viral ability to increase exacerbations involves 
lytic replication in animal models not observed in all human patients [99]. CMV 
and Influenza are unable to use this mechanism to cause exacerbations.
2.6 Bacterial infections
Bacterial infections are suspected to be a cause for acute IPF exacerbations. In 
mouse lung fibrosis models, Streptococcus pneumoniae initiated pulmonary fibrosis 
via its pore creating cytotoxin pneumolysin, which was preventable by treatment 
with clarithromycin or amoxicillin at 24 hours or 48 hours [112]. The evaluation 
of IPF patient lung microbiome reveals staphylococcus and streptococcus species’ 
presence in significant numbers during the disease progression [113]. The bacte-
rial load in IPF patients BAL was larger than controls and the species in abundance 
were Haemophilus, Streptococcus, Neisseria, and Veillonella [114]. In murine models, 
Pseudomonas aeruginosa infection did not lead to augmentation of bleomycin-
induced fibrosis [91].
2.7 Geographical and racial factors
To better understand the etiology of IPF, it is ideal for identifying geographical 
areas with more significant cases and evaluate the involved triggers. A study from 
Spain analyzed the IPF cases location and consistently highly polluted areas to 
recognize any risk factors [115]. Locations associated with the higher prevalence of 
IPF cases correlated maximally with the APM 2.5 μm exposure than other risk fac-
tors. Patients in such areas may need screening for IPF to identify these cases early 
in the disease course. A Japanese study identified substantial ethnic differences 
regarding the IPF disease course [116]. These studies are essential as they reveal the 
genetic trait polymorphisms associated with IPF. The incidence of IPF in males is 
2.7 times higher than in females in Japan, possibly due to more male smokers than 
females. Males also have higher mortality than females, with a mortality ratio of 
2.68 compared to that of 1.59 in the USA [117]. Clinical data on ethnic disparities 
with regards to IPF mortality are limited. Acute IPF exacerbation accounts for 
most deaths in IPF patients, and cardiac disease is a less frequent cause than in 
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Western countries. The variable used in the prognostification of IPF, such as age 
and gender, did not perform well in Japanese [118]. The GAP system fared poorly, 
and no substantial survival differences were noted in different IPF stages. Most 
Japanese carry single nucleotide polymorphisms (SNPs) rs2736100 in intron 2 of 
the TERT (Telomerase reverse transcriptase) gene, codes for the telomerase reverse 
transcriptase.
A retrospective study reviewed the ethnic and racial disparities in USA IPF 
outcomes using Organ Procurement and Transplantation Network data from 
1995 to 2003 [119]. Black and Hispanic patients tended to be female and younger 
at diagnosis than whites. More significant medical comorbidities (hypertension, 
diabetes mellitus, and poor performance) were observed in Black and Hispanic 
patients. Whites had more private insurance, college education and lived in better 
neighborhood areas. The age-adjusted mortality rate and risk of having double 
lung transplantation were higher in Blacks and Hispanics. The poor mortality 
was partly attributed to the poor lung function when they were listed for lung 
transplantation. Race might be a proxy marker for the genetic makeup producing 
a specific phenotype [119]. Another retrospective study done in the USA evaluated 
the ethnic and racial differences based on National Center for Health Statistics data 
from 1989 to 2007 [120]. Among the IPF total census, 87.2% were Whites,5.4% 
Hispanics, 5% Blacks, and others 2.2%. As mentioned in the prior study, Blacks 
and Hispanics were younger at diagnosis and death. When age and gender were 
controlled, the race was a significant predictor for IPF death with a similar IPF risk 
in all races. Hispanics were at an increased death risk from IPF than Whites and 
Blacks. Blacks had a higher risk of death from pulmonary hypertension and lung 
cancer than Whites and Hispanic patients. Hispanics were more likely to be coded 
with IPF than Whites and Blacks. The differences mentioned above are due to 
blacks dying at an early age and less likely to smoke than Whites. Access to health 
care has been inadequate due to the lack of medical insurance in Blacks.
2.8 Genetic factors
Familial causes of IPF constitute less than 5% of all cases, with at least two 
family members being affected [121]. The diagnostic criteria used to identify 
cases are similar to the one used for sporadic cases. Familial inheritance is via an 
autosomal dominant pattern with partial penetrance [122]. In 15% of familial 
cases, the cause is gene mutations encoding the ribonucleic acid (RNA)(TERC) or 
protein component (TERT) of the telomerase enzyme [123, 124]. Another 25% have 
sporadic or familial IPF with no telomerase RNA component (TERC) or telomerase 
reverse transcriptase (TERT) mutation but have circulating leucocyte telomere 
shortening [125]. A substantial congregation of familial cases was observed in the 
Finnish population [126]. ELMOD2, a gene on chromosome 4q31, has been identi-
fied as a susceptible gene for familial IPF [127]. A significant familial association 
has been detected with surfactant protein C and A2 gene mutation [121, 128]. 
Sporadic mutations of surfactant protein C gene are rarely associated with IPF 
[129]. A Mucin 5B (MUC5B) gene polymorphism of the promoter (rs35705950) is 
substantially associated with familial and sporadic IPF [130]. MUC5B promoter 
polymorphism presence can be used for IPF prediction and prognostification; 
however, it is not seen in 40% of cases [131, 132]. New loci (FAM13A, DSP, OBFC1, 
ATP11A, DPP9) and prior associations (TERT, MUC5B, TERC) were confirmed by 
a genome-wide association study in White patients. The newer loci were essential 
in immune defenses, DNA repair, and cell adhesion [133]. Peripheral blood mark-
ers may be used to identify a protein signature made up of MMP 1, MMP 7, MMP 
8, Insulin-like growth factor-binding protein 1(IGFBP1) & tumor necrosis factor 
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receptor superfamily member 1A (TNFRSA1F), which was able to differentiate IPF 
patients from healthy controls with a specificity of 98.1% and sensitivity of 98.6% 
[134]. Higher plasma concentrations of MMP 7, vascular cell adhesion molecule 1 
(VCAM-1), IL-8, Intercellular Adhesion Molecule 1 (ICAM-1), and S100 calcium-
binding protein A12 (S100A12) predict poor survival in IPF patients [135]. The gene 
microarray expression process can help in understanding the pathophysiology and 
therapeutic target candidates [136]. Currently, no genetic factors are associated 
with sporadic IPF in a consistent pattern.
3. Vital statistics and measures to improve them
Epidemiologic studies carried out before 2013 are highly heterogeneous in their 
methods and cannot be compared [137]. Even with this heterogeneity, the incidence 
shows a gradual increase across the world [138]. The IPF incidence has increased 
in all studies except for two quality studies, one each from Denmark and USA 
[139, 140]. When all studies are considered, the IPF incidence ranges from 0.22 to 
93.7 per 100,000 per year. After removing underreported, South American and 
Asian studies, the incidence was 2.8 to 9.3 per 100,000 per year for the USA and 
European studies together [138]. In Europe, the higher rates were observed in the 
UK, while Scandinavia and Southern Europe revealed lower rates [4, 139, 141–143]. 
In the USA, using the narrow criteria, the incidence rates were lower at an incidence 
of 5–8 per 100,000 per year [38, 144, 145]. Incidence rates in South America were 
at 0.4 to 1.2 per 100,000 per year [146, 147]. East Asia studies based on insurance 
claims indicate an incidence rate of IPF at 1.2–3.8 per 100,000 per year [148, 149]. 
In contrast, in Japan, the mortality statistics suggest a greater incidence rate and 
an adjusted mortality rate of 10.26 per 100,000 [150]. Age-adjusted mortality has 
accelerated from 3.2 per 100,000 in 1979 to 7.57 per 100,000 from 1999 to 2003 in 
USA [38, 151]. In the UK, age-adjusted mortality has increased from 2.54 per 100 
000 (1968–2008) to 5.5.10 per 100 000 (2005–2008) [141]. In Brazil, mortality had 
risen from 0.65 per 100 000 in 1996 to 1.21 per 100 000 in 2010 [146].
Overall, increased incidence rates are observed in the UK, European, South 
American, and East Asian epidemiological studies [141, 146–148, 152, 153]. USA 
mortality rates have declined as in Denmark after reaching a plateau [2, 139, 154]. 
Younger patients have a more prolonged median survival due to earlier treatment 
of recognized comorbidities and avoiding the use of ineffective treatment such as 
immunosuppressants and corticosteroids [117]. IPF diagnosis and treatment are 
getting more specific, and widespread acceptance of IPF international guidelines 
will improve accurate, comparable IPF clinical data [155]. National IPF registries 
from different countries will yield valuable data on IPF epidemiology. In general, 
the current IPF epidemiological data does not have substantial consistency.
The ideal sample should be large to validate the clinical diagnosis by medical 
records review [138]. Uncertainty of diagnosis can be avoided by using interna-
tionally accepted guidelines and consolidate its use in all studies. Other things to 
be considered are liberal use of imaging techniques, avoid broad diagnostic codes 
to identify IPF, and reinforce clinical guidelines in practicing physicians [138]. 
IPF score algorithm improved the positive predictive value by incorporating the 
IPF risk factors to identify fewer false-positive cases accurately [1]. The increas-
ing prevalence can be attributed to the IPF patients living longer than ten years 
before [117]. Prevalence is affected by disease definition, guidelines used for 
diagnosis, the difference in methodology, and health care systems. Gender differ-
ences are due to smoking habit variations and occupational exposure. Incidence 
is influenced by diagnostic improvements, population age, availability of drugs, 
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and improved health care. Mortality is affected by clinical recognition of IPF and 
diagnostic coding [155]. Insurance databases reveal an underrepresentation of lower 
socioeconomic strata and non-White patients, impacting the overall incidence 
and prevalence [1]. Care should be ascertained during medical record review for 
confirmation as they can be inaccurate. Using medicare beneficiary data excludes 
younger IPF patients, which a national IPF registry can avoid [117].
4. Conclusion
IPF datasets currently overestimate the prevalence, whereas the questionnaire 
studies underestimate it. Obtaining the correct epidemiological data is essential 
in identifying IPF clinical course and prognosis. Initiation and maintenance of 
a national registry with appropriate epidemiology data collection is an excellent 
beginning. An attempt should be garnered towards using algorithms or other tools 
in epidemiological studies to establish their efficacy. Epidemiological studies should 
attempt to use a similar case definition standardized across multiple countries to 
compare effectively and decrease the heterogeneity. As the IPF incidence increases, 
it has become a substantial public health concern. Future studies need to stress 
clinical epidemiology, pathophysiology & diagnostic biomarkers for an accurate 
understanding of epigenetic mechanisms and their pathways to provide a clue about 
future therapeutic targets. Clinical research into the epigenetic processes, disease 
pathophysiology, and diagnostic procedures needs to be encouraged and supported 
to improve life quality, prolong survival, and ultimately find a cure.
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PPV Positive predictive value
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COPD Chronic obstructive pulmonary disease
CPFE Combined pulmonary fibrosis and emphysema
CSE Cigarette smoke exposure
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GERD Gastroesophageal reflux disease
LES Lower esophageal sphincter
BAL Bronchoalveolar lavage
PPI Proton pump inhibitor






HCV Hepatitis C virus
TTV Torque-Teno virus
SNP Single nucleotide polymorphism
TERT Telomerase reverse transcriptase
RNA Ribonucleic acid
TERC Telomerase RNA component
MUC5B Mucin5b
FAM13A Family with sequence similarity 13, Member A
DSP Desmoplakin
OBFC1 Oligosaccharide-binding fold-containing Protein 1
ATP11A ATPase Phospholipid Transporting 11A
DPP9 Dipeptidyl Peptidase 9
IGFBP Insulin-like growth factor-binding protein
TNFRSA1F Tumor necrosis factor receptor superfamily member 1A
VCAM Vascular cell adhesion molecule
IL Interleukin
ICAM Intercellular adhesion molecule
S100A12 S100 calcium-binding protein A12
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